Pancreatic Cancer Research

ResearcherJuntendo UniversityNo recent work listed

Tetsuo Akimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0881-1345; OpenAlex author ID A5074150160. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper

Papers 7

  1. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  2. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Co-author DOI 10.1007/s00280-020-04206-w↗
  3. The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreatic cancer. Co-author DOI 10.1002/cam4.2954↗
  4. Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal t… Last author DOI 10.1186/s13014-020-01592-6↗
  5. Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pa… Last author DOI 10.3389/fonc.2020.517061↗
  6. Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001369↗
  7. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, pr… Co-author DOI 10.1136/bmjopen-2017-018445↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Ikeda · 4 shared papers, 2017–2022 · strength 0.40
  2. Motohiro Kojima · 4 shared papers, 2017–2022 · strength 0.40
  3. Atsushi Ochiai · 2 shared papers, 2019–2020 · strength 0.21
  4. Shinichiro Takahashi · 2 shared papers, 2017–2022 · strength 0.19
  5. Katsuhiko Uesaka · 2 shared papers, 2017–2022 · strength 0.19
  6. Vijay Parshuram Raturi · 2 shared papers, 2020 · strength 0.18
  7. Norihisa Takakura · 1 shared paper, 2022 · strength 0.12
  8. Wataru Kimura · 1 shared paper, 2022 · strength 0.12
  9. Masato Nagino · 1 shared paper, 2022 · strength 0.12
  10. Keishi Sugimachi · 1 shared paper, 2022 · strength 0.12
  11. Atsushi Miyamoto · 1 shared paper, 2022 · strength 0.12
  12. Hirochika Toyama · 1 shared paper, 2022 · strength 0.12
  13. Takehito Otsubo · 1 shared paper, 2022 · strength 0.12
  14. Soichiro Morinaga · 1 shared paper, 2022 · strength 0.12
  15. Satoshi Hirano · 1 shared paper, 2022 · strength 0.12
  16. Wataru Takayama · 1 shared paper, 2022 · strength 0.12
  17. Ikuhiro YAMADA · 1 shared paper, 2021 · strength 0.11
  18. Kumiko Umemoto · 1 shared paper, 2021 · strength 0.11
  19. Nobumasa Mizuno · 1 shared paper, 2021 · strength 0.11
  20. Takeshi Terashima · 1 shared paper, 2021 · strength 0.11
  21. Yukio Yoshida · 1 shared paper, 2021 · strength 0.11
  22. Junji Furuse · 1 shared paper, 2021 · strength 0.11
  23. Makoto Ueno · 1 shared paper, 2021 · strength 0.11
  24. Masayo Motoya · 1 shared paper, 2021 · strength 0.11
  25. Chigusa Morizane · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.